Coronary artery stents and non-cardiac surgery

British Journal of Anaesthesia

Volumn 98, Issue 5, 2007, Pages 560-574

  Howard Alpe, Georgina M ^a   de Bono, J ^b   Hudsmith, L ^b   Orr, W P ^c   Foex, P ^a   Sear, J W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Anaesthetic techniques, regional; Coronary stenosis, drug therapy; Platelet aggregation inhibitors, therapeutic use; Stents; Surgery, non cardiac

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 7; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 3A4; DIFLUNISAL; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; POLYMER; PROTHROMBIN; RAPAMYCIN; RITONAVIR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; BLEEDING TIME; CARDIOVASCULAR RISK; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ELECTIVE SURGERY; EMERGENCY SURGERY; HUMAN; HYPERCOAGULABILITY; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGIONAL ANESTHESIA; RESTENOSIS; RETREATMENT; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURGICAL MORTALITY; SURGICAL RISK; SURGICAL TECHNIQUE; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; CORONARY ARTERY OBSTRUCTION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG MONITORING; GRAFT OCCLUSION; METHODOLOGY; PERIOPERATIVE PERIOD; STENT; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GRAFT OCCLUSION, VASCULAR; HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; STENTS;

EID: 34250367071     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem089     Document Type: Review

References (135)

1. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104: 533-8
2. Agarwal S, Coakely M, Reddy K, Riddell A, Mallett S, Quantifying the effect of antiplatelet therapy: A comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105 676-83
3. Akowuah E, Shrivastava V, Jamnadas B, et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. Ann Thorac Surg 2005; 80: 149-52
4. Albaladejo P, Marret E, Piriou V, Samama CM. Perioperative management of antiplatelet agents in patients with coronary stents: Recommendations of a French Task Force. Br J Anaesth 2006; 97: 580-2
5. Allen JR, Helling TS, Hartzler GO. Operative procedures not involving the heart after percutaneous transluminal coronary angioplasty. Surg Gynecol Obstet 1991; 173: 285-8
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004; 25 1903-10
7. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: A word of caution. Ann Thorac Surg 2005; 79: 1210-6
8. Auer J, Berent R, Weber T, Eber B. Risk of noncardiac surgery in the months following placement of a drug-eluting coronary stent. J Am Coll Cardiol 2004; 43: 713, author reply 714-15
9. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-91
10. BARI. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335: 217-25
11. Begg A, Jennings K, Ritchie L, et al. Management of stable angina. A National Clinical Guideline. The Scottish Intercollegiate Guidelines Network (SIGN) 2007; 96: 23-4
12. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14
13. Brabandt HV. Stent thrombosis: Antiplatelets alone won't do the job. Br Med J 2007; 334: 57
14. Breen P, Lee JW, Pomposelli F, Park KW. Timing of high-risk vascular surgery following coronary artery bypass surgery: A 10-year experience from an academic medical centre. Anaesthesia 2004; 59: 422-7
15. Brilakis ES, Orford JL, Fasseas P, et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol 2005; 96: 512-4
16. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 2007; 98: 19-22
17. Brown MJ, Long TR, Brown DR, Wass CT. Acute coronary syndrome and myocardial infarction after orthopedic surgery in a patient with a recently placed drug-eluting stent. J Clin Anesth 2006; 18: 537-40
18. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257: 399-414
19. Charbucinska KN, Godet G, Itani O, et al. Anticoagulation management for patients with drug-eluting stents undergoing vascular surgery. Anesth Analg 2006; 103: 261-3
20. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004; 78: 1536-41
21. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-7
22. Colombo A, Iakovou I. Drug-eluting stents: The new gold standard for percutaneous coronary revascularisation. Eur Heart J 2004; 25 895-7
23. Coolong A, Mauri L. Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped? Curr Cardiol Rep 2006; 8: 267-71
24. Costa MA, Simon DI. Molecular basis of re-stenosis and drug-eluting stents. Circulation 2005; III: 2257-73
25. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified thrombelastograph and plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 309-15
26. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-45
27. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-71
28. Dent H, Lekic Z, Vicenzi M. Unfractionated heparin and coronary artery stenting. Br J Anaesth 2006; 97: 582
29. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105: 1257-67
30. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110 340-437
31. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 34: 1262-347
32. Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: Influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 1997; 96: 1882-7
33. Eikelboom JW, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003; 14: 713-7
34. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5
35. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003; 42: 1-6
36. Ellis SG, Bajzer CT, Bhatt DL, et al. Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc Interv 2004; 63 135-40
37. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9
38. Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 2006; 151: 373-9
39. Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345: 1677-82
40. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8
41. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5
42. Gersh BJ, Rihal CS, Rooke TW, Ballard DJ. Evaluation and management of patients with both peripheral vascular and coronary artery disease. J Am Coll Cardiol 1991; 18: 203-14
43. Gershlick AH, Richardson G. Drug eluting stents. Br Med J 2006: 333: 1233-4
44. Godet G, Riou B, Bertrand M, et al. Does preoperative coronary angioplasty improve perioperative cardiac outcome? Anesthesiology 2005; 102: 739-46
45. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-44
46. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-902
47. Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc 2000; 75: 1116-23
48. Grech ED. ABC of interventional cardiology: Percutaneous coronary intervention. II: The procedure. Br Med J 2003; 326: 1137-40
49. Grossmann R, Sokolova O, Schnurr A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-6
50. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006; 19: 439-48
51. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367 606-17
52. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43: 963-81
53. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18: 149-65
54. Herbstreit F, Peters J. Spinal anaesthesia despite combined clopidogrel and aspirin therapy in a patient awaiting lung transplantation: Effects of platelet transfusion on clotting tests. Anaesthesia 2005; 60 85-7
55. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64SM-94S
56. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-50
57. Hochholzer W, Trenk D, Frundi D, Neumann FJ. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res 2007; 119: 285-91
58. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172-97
59. Huber KC, Evans MA, Bresnahan JF, Gibbons RJ. Holmes DR jr. Outcome of noncardiac operations in patients with severe coronary artery disease successfully treated preoperatively with coronary angioplasty. Mayo Clin Proc 1992; 67: 15-21
60. Hudsmith L, De Bono J, Mckenna C, P F, WP O. Dual antiplatelet therapy and non-cardiac surgery risk; what are the anaesthetists and surgeons doing? Eur Heart J 2006; 27: 380-1
61. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30
62. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94
63. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005; 96: 750-5
64. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-8
65. Kovesi T, Royston D. Is there a bleeding problem with platelet-active drugs? Br J Anaesth 2002; 88: 159-63
66. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71
67. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-7
68. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Re-stenosis Study Investigators. N Engl J Med 1998: 339: 1665-71
69. Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005; 80: 928-33
70. Litz RJ, Gottschlich B, Stehr SN. Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin. Anesthesiology 2004; 101: 1467-70
71. Mahla E, Lang T, Vicenzi MN, et al. Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg 2001; 92: 572-7
72. Marcucci C, Chassot PG, Gardaz JP, et al. Fatal myocardial infarction after lung resection in a patient with prophylactic preoperative coronary stenting. Br J Anaesth 2004; 92: 743-7
73. Marx SO, Marks AR. Bench to bedside: The development of rapamycin and its application to stent re-stenosis. Circulation 2001; 104: 852-5
74. Mason JJ, Owens DK, Harris RA, Cooke JP, Hlatky MA. The role of coronary angiography and coronary revascularization before noncardiac vascular surgery. JAMA 1995; 273: 1919-25
75. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100: 1576-83
76. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21
77. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795-804
78. Mehta DK, ed. British National Formulary, 51 Edn. London: BMJ Publishing Group Ltd and RPS Publishing, 2006
79. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: A multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cordiol 2001; 38: 143-9
80. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23
81. Moses JW, Stone GW, Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: Pooled analysis from four randomized trials. J Am Coll Cordial 2006; 47: 2164-71
82. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3
83. Murphy JT, Fahy BG. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit, Anesth Analg 2005; 101: 971-3
84. Nordmann AJ, Briel M, Bucher HC, Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006; 27: 2784-814
85. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43: 1711-6
86. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and sixmonth clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-53
87. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cordiol 2006; 98: 352-6
88. Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg 2002; 35: 1204-9
89. Payne EM, Brett SJ, Laffan MA. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: A single centre experience. Blood Coagul Fibrinolysis 2006; 17: 397-402
90. Pennefather SH, Gilby S, Danecki A, Russell GN. The changing practice of thoracic epidural analgesia in the United Kingdom: 1997-2004. Anaesthesia 2006; 61: 363-9
91. Posner KL, Van Norman GA, Chan V. Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Anesth Analg 1999; 89: 553-60
92. Pothula S, Sanchala VT, Nagappala B, Inchiosa MA jr. The effect of preoperative antiplate/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery. Anesth Analg 2004; 98: 4-10
93. Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006; 92: 531-2
94. Radford MJ. Percutaneous coronary intervention 'dominates' coronary artery bypass graft surgery for high-risk patients: Good news for patients, a challenge for healthcare planners. Circulation 2006; 114: 1229-31
95. Ray JG, Deniz S, Olivieri A, et al. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. BMC Cardiovasc Disord 2003; 3: 3
96. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005; 95: 755-7
97. Rosenfeld BA, Beattie C, Christopherson R. et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology 1993: 79: 435-43
98. Royston D, Levy JH, Fitch J, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: An analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006; 103 1082-8
99. Samama CM, Djoudi R, Lecompte T, Nathan-Denizot N, Schved JF. Perioperative platelet transfusion: Recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Can J Anaesth 2005; 52: 30-7
100. Samama CM, Djoudi R, Lecompte T, Nathan N, Schved JF. Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiol 2006; 72: 447-52
101. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001; 94: 74-8
102. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9
103. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80
104. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24
105. Serry R, Penny WF. Endothelial dysfunction after sirolimus-eluting stent placement. J Am Coll Cardiol 2005; 46: 237-8
106. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: When is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141-5
107. Shuchman M. Trading re-stenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949-52
108. Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47
109. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5
110. Smith SC, jr, Feldman TE, jr, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: E166-286
111. Smith SM, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 15: 465-74
112. Smout J, Stansby G. Current practice in the use of antiplatelet agents in the peri-operative period by UK vascular surgeons. Ann R Coll Surg Engl 2003; 85: 97-101
113. SoS. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial [SoS]): A randomised controlled trial. Lancet 2002; 360: 965-70
114. Spahn DR, Howell SJ, Delabays A, Chassot PG. Coronary stents and perioperative anti-platelet regimen: Dilemma of bleeding and stent thrombosis. Br J Anaesth 2006; 96: 675-7
115. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20
116. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: Focus on the role of antiplatelet therapy. Mayo Clin Proc 2006; 81: 641-52
117. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31
118. Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 2006; 114: 1251-7
119. Tabuchi Y, Nosaka S, Amakata Y, Takamitsu Y, Shibata N. Perioperative management for nephrectomy in a long-term hemodialysis patient with anticoagulants for coronary stent. Masui 1998; 47: 720-5
120. Tam NL, Pac-Soo C, Pretorius PM. Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin. Br J Anaesth 2006; 96: 262-5
121. Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH. Clopidogrel (Plavix) and cardiac surgical patients: Implications for platelet function monitoring and postoperative bleeding. Platelets 2004; 15: 325-32
122. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-6
123. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj, M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery - a prospective outcome study. Br J Anaesth 2006; 96: 686-93
124. Vicenzi MN, Ribitsch D, Luha O, Klein W, Metzler H. Coronary artery stenting before noncardiac surgery: More threat than safety? Anesthesiology 2001; 94: 367-8
125. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-5
126. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006; 27: 647-54
127. Ward HB, Kelly RE, Thottapurathu L, et al. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann Thorac Surg 2006; 82: 795-800; discussion 800-1
128. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001; 52 333-6
129. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-52
130. Wheeler GL, Braden GA, Steinhubl SR, et al. The Ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002; 143: 602-11
131. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-40
132. Worthley MI, Anderson TJ, Traboulsi M, et al. Registry data evaluating the effectiveness of drug-eluting stents for the treatment of symptomatic in-stent re-stenosis. Heart Lung Circ 2006; 15: 300-5
133. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001; 29: 2271-5
134. Zimarino M, Renda G, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents, Drugs 2005; 65: 725-32
135. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105: 1034-46